PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...

Heidi Crayton, MD, and Maria Lopes, MD, discuss the most recent 2018 guidelines for multiple sclerosis treatment, emphasizing the need for updated guidelines, particularly in the payer space, to ...

The updated guidelines were presented at last week's European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, and the result of a collaboration between ECTRIMS and the ...

Dr Haumschild leads a discussion surrounding patient and provider collaboration to avoid clinical inertia in MS treatment pathways. Ryan Haumschild, PharmD, MS, MBA: One of the things I see is, ...

Starting high-efficacy monoclonal antibody therapy during childhood reduced long-term disability in pediatric-onset multiple sclerosis (MS), registry data suggested. Among 282 patients with ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study published in ...

In a significant advance for multiple sclerosis (MS) research, a new study has uncovered a potential link between certain initial symptoms and long-term disability outcomes. The research, published in ...

We know so much more about multiple sclerosis (MS) than we used to. But one important theme is that we’ve become much better at treating the relapsing form of this disease and changing its natural ...